Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 50 15 versus CAPTOPRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 50 15 versus CAPTOPRIL.
CAPOZIDE 50/15 vs CAPTOPRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAPOZIDE 50/15 combines captopril (angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (thiazide diuretic). Captopril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- cotransporter in distal convoluted tubules.
Competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion.
Oral, 1 tablet (captopril 50 mg / hydrochlorothiazide 15 mg) once daily. May increase to 2 tablets daily in divided doses if needed.
Initial: 25 mg PO 2-3 times daily; target dose: 50 mg PO 2-3 times daily; maximum: 450 mg/day. For heart failure: start 6.25-12.5 mg PO 3 times daily, titrate to 25-50 mg PO 3 times daily.
None Documented
None Documented
Clinical Note
moderateCaptopril + Benzydamine
"The risk or severity of adverse effects can be increased when Captopril is combined with Benzydamine."
Clinical Note
moderateCaptopril + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Captopril."
Clinical Note
moderateCaptopril + Droxicam
"The risk or severity of adverse effects can be increased when Captopril is combined with Droxicam."
Clinical Note
moderateCaptopril + Loxoprofen
Captopril: terminal half-life ~2 hours (in patients with normal renal function; prolonged in renal impairment to 21-36 hours). Hydrochlorothiazide: half-life 6-15 hours (mean ~9 hours; prolonged in renal impairment). Clinical context: dosing interval affected by renal function.
Terminal half-life 1.9 hours, prolonged to 3.5-32 hours in renal impairment; clinical context: requires adjusted dosing in renal failure
Captopril: renal excretion of unchanged drug and metabolites, primarily in urine (60-75%), with ~20% as unchanged captopril; small amount in feces (5-10%). Hydrochlorothiazide: renal excretion (95% unchanged), <5% via biliary/fecal.
Primarily renal (50-60% unchanged), with minor biliary/fecal elimination (<5%)
Category C
Category D/X
ACE Inhibitor and Diuretic Combination
ACE Inhibitor
"The risk or severity of adverse effects can be increased when Captopril is combined with Loxoprofen."